A New Breakthrough in the Fight Against Aggressive Breast Cancer
Research Updates
January 12, 2026
In an exciting development, scientists from the University of California San Diego have uncovered a novel treatment target for triple-negative breast cancer (TNBC), which is known as the most aggressive form of breast cancer. Their recent study has highlighted the critical role of a protein named PUF60 in enabling TNBC cells to grow and thrive by orchestrating the splicing of vital genes. When the function of PUF60 was disrupted in laboratory models of TNBC, it led to significant errors in gene processing, resulting in DNA damage, halting the cell cycle, and ultimately causing the death of tumor cells. Notably, this disruption did not adversely affect healthy cells, suggesting a targeted approach could be possible.
Triple-negative breast cancer is notoriously challenging to treat because it tends to be particularly aggressive and does not respond to standard targeted therapies that can be effective for other breast cancer types, such as immunotherapy or hormone therapies. As a result, patients diagnosed with TNBC often face a grim prognosis. To bridge the gap in treatment options for this formidable cancer type, researchers are actively seeking innovative strategies to target its unique characteristics, including attacking the molecular components that cancer cells rely on for their survival.
Some of the key insights from this groundbreaking study include:
- Through an extensive screening of over 1,000 RNA-binding proteins in TNBC cells, the team identified 50 crucial proteins necessary for the survival of these aggressive cancer cells, with PUF60 rising to prominence as a key candidate.
- Silencing PUF60 or introducing a specific mutation that interferes with its function resulted in major errors in DNA processing, ultimately leading to cell death in TNBC models.
- In various mouse models of TNBC, the absence of PUF60 resulted in significant tumor shrinkage, indicating its vital role in tumor growth.
- Remarkably, healthy breast cells appeared to remain largely unharmed when PUF60 was lost, reinforcing the potential for targeted treatments.
This research underscores the potential of targeting PUF60-mediated RNA splicing as a promising therapeutic strategy for not only TNBC but potentially for other cancers that exhibit replication stress. By identifying PUF60 as a crucial regulator for cancer cells—while being dispensable for healthy cells—these findings open up new avenues for drug development. However, it’s important to note that additional research is needed to determine if inhibitors that target PUF60 or its splice-site interactions can be effectively developed as targeted therapies for cancer treatment.
This study, published in Cancer Research, was led by Dr. Corina Antal, an assistant professor, alongside Dr. Gene Yeo, a professor, both affiliated with the UC San Diego School of Medicine and members of the UC San Diego Moores Cancer Center.
Stay Informed
Keep abreast of the latest developments from UC San Diego by subscribing to our newsletter today.
